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Abstract We isolated several clones from a matchmaker two-
hybrid system human lymphocyte cDNA library using an
automodification domain of poly(ADP-ribose) synthetase
(PARS) as a probe. A DNA sequence (V1 kbp) of the clone
was identical to part of the Oct-1 DNA sequence. We then
constructed either a His-tagged or GST fusion protein of the
inserted cDNA from the clone and the fusion protein was shown
to interact with PARS by far-Western blot analysis and co-
precipitation with affinity resin. Furthermore, the His-tagged
Oct-1/POU-homeo fusion protein interacted weakly with the
octamer motif of the DRa promoter and the addition of PARS
fusion protein greatly increased the DNA binding activity. These
results suggest that PARS interacts with Oct-1 and stabilizes the
binding of Oct-1 to the octamer motif.
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1. Introduction
Poly(ADP-ribose) synthetase (NAD ADP-ribosyltransfer-
ase, EC 2.4.2.30, PARS) is a chromatin-bound enzyme that
catalyzes the transfer of the ADP-ribose moiety of NAD to
nuclear proteins including the enzyme itself [1^4]. PARS was
proposed to mediate stress-induced signaling and also func-
tion in DNA repair processes [5]. Although poly(ADP-ribo-
syl)ation takes place under conditions in which chromatin is
damaged, a highly limited amount of poly(ADP-ribosyl)ated
nuclear protein was detected in intact cells [6]. Therefore, the
physiological roles of PARS in intact cells are still unclear.
PARS is also suggested to be involved in di¡erentiation.
PARS content critically changes during cell di¡erentiation
[7^9]. PARS mRNA level decreased during granulocytic dif-
ferentiation of HL-60 cells [10], erythrocytic di¡erentiation of
K562 [11] and neutrophilic di¡erentiation of acute promyelo-
cytic NB4 leukemia cells [12]. The neutrophilic di¡erentiation
of NB4 cells was inhibited by overexpression of PARS [13].
However, when an increase in PARS expression was pre-
vented in stably transfected 3T3-L1 preadipocyte cells by in-
duction of PARS antisense RNA synthesis, the cells did not
di¡erentiate [14]. Thus, the amount of PARS or activity of the
enzyme may associate with the signaling pathway of di¡er-
entiation. A periodic repetition of leucine residues has been
proposed to mediate homo- and hetero-dimer formation in-
volved in the DNA binding and function of these leucine
zipper proteins [15,16]. The presence of such phylogenetically
conserved motifs in the automodi¢cation domain of PARS
has been suggested to be responsible for the protein-protein
interactions involving PARS homo- and/or hetero-dimeriza-
tion with other nuclear leucine zipper proteins [17]. Thus,
PARS possibly interacts with a nuclear protein which is in-
volved in di¡erentiation processes and therefore we searched
for a protein(s) which interacted with PARS. Here we report
that Oct-1 interacts with the automodi¢cation domain of
PARS and binding of PARS stabilizes the binding of Oct-1
to the octamer sequence.
2. Materials and methods
2.1. Yeast strains and screening of two-hybrid B-cell cDNA library
Matchmaker Two-Hybrid System was obtained from Clontech
(Clontech Laboratories, Inc., USA). Yeast strain HF7c was used for
screening the human B-cell cDNA library. The pGBT-PARS/AMD
(automodi¢cation domain of PARS) was constructed by insertion of
the EcoRI/PstI 0.7 kbp fragment of PARS cDNA (pcD-ARS) [18]
into the EcoRI and PstI site of pGBT 9. pGBT-PARS/AMD and
the pACT-cDNA fusion library were cotransformed into HF7c using
the lithium acetate procedure. Double transformant cells grown on
Leu3, Trp3, His3 plates were incubated for 5 days at 30‡C. Positive
colonies were picked up, and assayed for the lacZ phenotype. The
selected clones were tested for their ability to transactivate with the
following non-speci¢c partners: pGBT 9, pGBT-PARS/AMD,
pLAM5P or pVA3. Filter assay for L-galactosidase activity was per-
formed according to the manufacturer’s protocols.
2.2. DNA sequencing
The library clones that grew up in the Leu3, Trp3, His3 plates only
in the presence of pGBT-PARS/AMD were chosen for DNA sequenc-
ing. DNA sequence was determined using sequencing primers 5P-
TACCACTACAATGGATG (reading toward the junction of the
GAL4 activation domain and the cloned candidate interacting pro-
tein) or 5P-ACGATGCACAGTTGAAG (reading reversely from
downstream of the multi-cloning site) with the ABI PRISM Genetic
Analyzer Model 310 (Applied Bio-systems), using the ABI PRISM
dye-terminator cycle sequencing ready reaction kit (Applied Biosys-
tems).
2.3. Construction of fusion proteins
His-tagged Oct-1/homeo was constructed by insertion of the XhoI
fragment of the 2-5-2 clone from the two-hybrid cDNA library into
the SalI site of pQE30 or the SalI site of pGST-5X-1. The Oct-1/
POU-homeo cDNA was synthesized by RT-PCR and subcloned
into the KpnI and BamHI site of pQE31 expression vector. His-tagged
PARS/AMD was constructed by subcloning of the KpnI/PstI frag-
ment of pcD-ARS [18] into the KpnI and PstI site of pQE32. The
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Fig. 1. Comparison of the DNA sequence of clone 2-5-2 and human Oct-1 (A) and schematic presentation of the corresponding part of clone
2-5-2 (Oct-1/Homeo) and Oct-1/POU-homeo synthesized by RT-PCR (B).
J. Nie et al./FEBS Letters 424 (1998) 27^3228
His-tagged fusion protein was puri¢ed on a Ni2-NTA resin column
(Qiagen), dialyzed in a bu¡er (20 mM Tris-HCl, pH7.5, 50 mM NaCl,
1 mM EDTA, 10% glycerol, 5 mM MgCl2) and used directly for
experiments. The pGST/Oct-1/homeo expression vector was trans-
formed into Escherichia coli BL21. The fusion protein was puri¢ed
on a glutathione-Sepharose column (Pharmacia) from the extract of
IPTG-induced transformant.
2.4. Far-Western blot analysis
His-tagged Oct-1/homeo fusion protein was prepared as described
above, separated on 10% SDS-PAGE and then transferred onto a
PVDF membrane. After soaking in 5% skim milk-TBBN (20 mM
Tris-HCl pH 7.5, 50 mM NaCl, 10 mM MgCl2, 0.1% NP-40) for
1 h at 25‡C, the membrane was incubated overnight with POD-la-
beled His-tagged PARS/AMD in 0.1% skim milk-TBBN at 4‡C [19].
Finally the band was visualized by a chemiluminescence detection
system (ECL) according to the manufacturer’s instructions (Amer-
sham).
2.5. In vitro binding studies
Glutathione S-transferase (GST) or GST-Oct1-homeo (5 Wg each)
was incubated with His-tagged PARS/AMD (10 Wg) in binding bu¡er
(50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 10% glyc-
erol, 0.5 mg/ml BSA, 5 mM 2-mercaptoethanol) at 4‡C overnight.
20 Wl of 50% glutathione-Sepharose 4B slurry (Pharmacia) was added
and after rotation for 1 h at 4‡C, the beads were sedimented and
washed 4 times with 400 Wl of binding bu¡er. The bound proteins
were eluted from the beads with 1 mg/ml glutathione in the same
binding bu¡er. The proteins were separated by SDS-PAGE and
then transferred to a PVDF membrane. The His-tagged PARS/
AMD fusion protein was detected by incubation with a polyclonal
anti-bovine PARS antibody, followed by POD-labeled second anti-
body and then visualized by the ECL detection system (Amersham).
2.6. Electrophoretic mobility shift assay (EMSA)
For the Oct-1 binding reaction, a probe was synthesized using 32P-
labeled primer to amplify the HLA-DRK promoter region in
pAKR5214-3 which contains the human genomic HLA-DRK gene
[20,21]. His-tagged Oct-1/POU-homeo protein (1.2 Wg) or His-tagged
PARS/AMD protein (0.5 Wg) was preincubated with 0.05 Wg poly(dI-
dC) (Pharmacia) for 30 min at 25‡C in a bu¡er containing 10 mM
Tris-HCl, pH 7.5, 50 mM NaCl, 10 mM MgCl2, 5 mM CaCl2, 5%
glycerol, 1 mM EDTA. An aliquot of 5000 cpm (V6 ng) of the 32P-
labeled double strand DNA probe was thereafter added in a ¢nal
reaction volume of 10 Wl and the incubation was continued for an-
other 30 min. Reaction components were separated on a 3.5% poly-
acrylamide (30:1 Bis) gel in 0.5UTBE bu¡er at 100 V for 60 min. The
DNA-protein complex was visualized by autoradiography. Anti-
PARS protection assay was performed as follows: PARS/AMD was
incubated with anti-PARS antibody (3 or 6 Wg of IgG) at 25‡C for 30
min, and then Oct-1/POU-homeo and 32P-labeled DRK DNA probe
were added. The complex was analyzed as described above.
3. Results
3.1. Screening of cellular proteins that interact with the
automodi¢cation domain of PARS
The yeast two-hybrid system used to screen for cDNA en-
coding cellular proteins able to interact with a target protein
of interest is well known [22^24]. To identify proteins that
interact with the automodi¢cation domain of PARS, this re-
gion was subcloned into plasmid pGBT9 to be expressed as a
fusion protein with the DNA binding domain of the Gal 4
protein (pGBT-PARS/AMD). The cDNA library proteins
were constructed with a pACT plasmid such that fusions be-
tween the cDNA-encoding proteins and the Gal 4 activation
domain were generated. The two types of hybrid plasmids
were then cotransformed into the yeast host strain HF7c.
About 1.5U105 pGBT-PARS/AMD and pACT-cDNA dou-
ble transformants were screened for His-independent growth.
33 clones were isolated as His transformants. His trans-
formants were further assayed for color development in the
L-galactosidase assay and 12 transformants were found
among 33 His transformants to be L-galactosidase-positive.
As some pACT-cDNA-expressed proteins may interact non-
speci¢cally with fusion proteins, expressed by pGBT9 plas-
mids, false-positive clones frequently appear in the screening
procedure. To eliminate false-positive clones, a con¢rmation
test was performed. pACT-cDNA plasmids were cotrans-
formed with either pGBT9, pLAM5P, pVA3 or pGBT-
PARS/AMD into HF7c and then tested for His-independent
growth. In this test, clones that grew in His-de¢cient medium
only in the presence of pGBT-PARS/AMD were considered
to be true positive clones. Only six clones survived all the
genetic tests and were analyzed further.
3.2. Sequence analysis of the positive pACT-cDNA clone 2-5-2
The pACT-cDNA plasmids were recovered from the six
selected clones and sequenced. Sequence homology searches
in GenBank revealed that the sequence of a clone, named 2-5-
2 (approximately 1 kbp insert DNA), was almost identical to
the human lymphoid-speci¢c Oct-1 from bp 1048 to 1995
(Fig. 1) [25]. Oct-1 has a unique DNA binding POU domain
(894^1121) and a homeo domain (1194^1373). The predicted
amino acid sequence of the 2-5-2 plasmid contains the whole
homeo domain and a part of the POU domain, lacking the N-
terminal 330 amino acids.
3.3. Interaction of Oct-1 and automodi¢cation domain of
PARS in vitro
To demonstrate the direct interaction between PARS and
Oct-1/homeo, we constructed a His-tagged fusion protein by
ligating the XhoI fragment of the 2-5-2 plasmid with the SalI
site of pQE vector. The fusion protein was induced by IPTG
and isolated with Ni-NTA resin column. The a⁄nity-puri¢ed
fusion protein was analyzed by far-Western blot analysis with
the POD-labeled His-tagged PARS/AMD protein as a probe.
The fusion protein migrated with an apparent molecular
weight of 38 kDa, which was in agreement with the size de-
duced from the cDNA sequence. An identical gel was trans-
blotted onto a PVDF membrane and subsequently incubated
with POD-labeled His-tagged PARS-AMD. The band corre-
sponding to His-tagged Oct-1/homeo was visualized by ECL
(Fig. 2A). The result indicates that the Oct-1/homeo fusion
protein interacted with His-tagged PARS-AMD.
In the far-Western blot analysis, one of the two interaction
partners was denatured and subsequently renatured. There-
fore, we further decided to examine whether the two proteins
would also be able to interact in solution when they are
present as a native conformation in solution. Thus, we con-
structed a GST fusion protein with the XhoI fragment of the
2-5-2 plasmid and performed an in vitro binding assay. The
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Fig. 3. A: EMSA was performed with DRK promoter DNA, which contains the typical octamer sequence as a probe as described in Section 2.
Lane 1: no protein; lane 2: His-tagged Oct-1/POU-homeo (1.2 Wg); lane 3: His-tagged Oct-1/POU-homeo (1.2 Wg) and His-tagged PARS/
AMD (0.5 Wg); lane 4: His-tagged PARS/AMD (0.5 Wg). White arrow and black arrow indicate Oct-1/POU-homeo-DRa DNA complex and
Oct-1/POU-homeo-PARS-DRa DNA complex, respectively. B: E¡ect of anti-PARS antibody on the binding of OCT-1/POU-homeo and
PARS/AMD complex to the DRK promoter DNA. PARS/AMD was incubated in the absence of (lane 1) or in the presence of anti-PARS anti-
body (0.8, 1.6 or 3.2 Wg of IgG for lanes 2, 3 or 4, respectively) for 30 min at 25‡C, and then Oct-1/POU-homeo and 32P-labeled DRK DNA
probe were added.
Fig. 2. A: Interaction of Oct-1/homeo or Oct-1/POU-homeo with PARS/AMD analyzed by far-Western blot analysis. The a⁄nity-puri¢ed His-
tagged Oct-1/homeo (4.6 Wg) (lane 1) or Oct-1/POU-homeo (18 Wg) (lane 2) was subjected to SDS-PAGE and transferred onto a PVDF mem-
brane. The protein on the membrane was reacted with POD-labeled His-tagged PARS/AMD and visualized with ECL kit (Amersham). Lanes
3 and 4 shows SDS-PAGE protein-stained pattern of the a⁄nity-puri¢ed His-tagged Oct-1/homeo and Oct-1/POU-homeo fusion proteins, re-
spectively. An arrowhead indicates the position of puri¢ed His-tagged Oct-1/homeo. Standard molecular sizes of marker proteins are shown on
the right. B: Interaction of GST-Oct-1/homeo with PARS/AMD, analyzed by co-precipitation with an a⁄nity resin. His-tagged PARS/AMD
was incubated with either GST control protein (lane 1) or GST-Oct-1/homeo (lane 2) and the complex was precipitated with a glutathione-a⁄n-
ity resin. The bound proteins were resolved by SDS-PAGE, transferred onto a PVDF membrane and then reacted with anti-PARS antibody
and POD second antibody followed by visualization using an ECL kit. Lane 3 shows CBB-stained His-tagged PARS/AMD.
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puri¢ed GST protein or the GST-Oct-1/homeo fusion protein
was incubated with His-tagged PARS/AMD at 25‡C, and
then glutathione-Sepharose resin was added to the reaction
mixture. After washing, the a⁄nity resin complex was incu-
bated in an elution bu¡er containing glutathione. The eluate
was subjected to SDS-PAGE and transferred onto a PVDF
membrane. The membrane was stained by anti-PARS anti-
body and POD-labeled second antibody. The His-tagged
PARS/AMD was recovered with the GST-Oct-1 fusion pro-
tein but not with GST control (Fig. 2B). These observations
show that Oct-1/homeo binds to PARS/AMD without the
intermediary of third proteins or DNA and does so in a
cell-free system as well as in yeast.
3.4. The PARS/AMD and Oct-1/POU-homeo complex bind
DNA cooperatively
A question to be solved was whether the physical interac-
tion between Oct-1 and PARS would have any functional
consequences. We therefore investigated whether the interac-
tion of these two proteins would a¡ect the sequence-speci¢c
DNA binding of the Oct-1/POU-homeo protein. Comparison
of the 2-5-2 sequence with intact Oct-1 sequence indicated
that the 2-5-2 clone was lacking a part of the helix-loop-helix
POU domain as described above. To perform EMSA, we
synthesized an upper primer designed in upstream of POU
domain and a lower primer designed near the end of the 2-
5-2 cDNA and produced 1 kbp Oct-1/POU-homeo cDNA by
RT-PCR. The cDNA was inserted into pQE vector and His-
tagged Oct-1/POU-homeo fusion protein was puri¢ed from E.
coli M15. The octamer sequence element of the HLA-DRa
promoter was used as a probe. Under those conditions of
limiting amounts of puri¢ed Oct-1/POU-homeo protein, a
weak but signi¢cant interaction was observed between Oct-
1/POU-homeo protein and the octamer sequence of the
DRK promoter (Fig. 3A, lane 2). When the His-tagged
PARS/AMD was added to the Oct-1/POU-homeo protein, a
prominent retarded complex was observed (Fig. 3A, lane 3).
The PARS/AMD protein itself did not interact with the probe
(Fig. 3A, lane 4). The result indicates that the complex of Oct-
1/POU-homeo and PARS/AMD associates with the octamer
sequence more tightly than free Oct-1/POU-homeo. To con-
¢rm whether the further shifted band was due to the binding
of PARS/AMD, we incubated PARS/AMD with antibody
against His-tagged PARS/AMD, and then Oct-1/POU-homeo
and 32P-labeled DRK DNA probe was added. An excess
amount of the antibody diminished the shifted band (Fig.
3B, lane 4). The same amount of pre-immune IgG did not
a¡ect the binding (data not shown). These results indicate that
Oct-1/POU-homeo interacts with PARS/AMD and the com-
plex associates with the octamer sequence cooperatively.
4. Discussion
We have demonstrated that Oct-1 interacts with the auto-
modi¢cation domain of PARS (PARS/AMD) and this inter-
action increased the a⁄nity of Oct-1 for the octamer motif of
the DRK promoter. Octamer consensus sequence has been
located in the promoters of several genes, some of which
play an important role in cell cycle and di¡erentiation.
Among these genes, the binding of Oct-1 to the octamer motif
stimulated the transcription of the immunoglobulin gene [26]
and the histone H2B gene [27]. Emerging evidence suggests
that transcriptional activation via Oct-1 is dependent upon
interactions with additional proteins such as Pit-1 [28], OAP
[29] or VP16 [30]. In contrast, Oct-1 has also been shown to
act as a transcriptional repressor for a number of regulatory
regions such as the IL-8 promoter [31]. It has also been re-
ported that Sp1 and Oct-1 interact physically to regulate hu-
man U2 snRNA gene expression [32]. Thus, Oct-1 is a target
for both positive and negative regulation by protein-protein
interaction. The overall level of transcriptional activity is de-
termined by the balance between the binding of Oct-1 and the
particular transcriptional activator [33]. Recently Roeder and
his group reported that PARS is one functional component of
the positive cofactor activity and it enhanced transcription by
acting during preinitiation complex formation, but at a stage
after binding of transcription factor IID [34]. Considering
these observations, the association between Oct-1 and PARS
seems to a¡ect, either positively or negatively, essential tran-
scription or tissue-speci¢c transcription. If PARS competes
with these essential transcriptional factors to bind to Oct-1,
it is possible that transcription is regulated by the interaction
with PARS.
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